The Need: Antimicrobial Breakthrough for Avian Bacterial Infections

Avian species, particularly chickens and turkeys, face significant economic losses due to bacterial infections caused by pathogenic Escherichia coli (APEC) and Salmonella strains (ST and SE). These bacteria not only harm avian populations but also pose serious health risks to humans through contaminated poultry products. Current treatments relying on antimicrobial drugs have limited effectiveness and contribute to the emergence of antibiotic-resistant strains, exacerbating the problem. There is a pressing need for an advanced antimicrobial solution that can effectively combat avian bacterial infections while minimizing the risk of resistance development.

The Technology: Advanced Antimicrobial Peptide Therapy

The technology presents a groundbreaking antimicrobial peptide therapy for treating and preventing bacterial infections in avian species. The composition consists of an antimicrobial peptide, with an amino acid sequence closely resembling specific identified sequences (SEQ ID NO: 21, SEQ ID NO: 32, SEQ ID NO: 85, SEQ ID NO: 86, or SEQ ID NO: 87), or their functional variants. This peptide is administered with a pharmaceutically acceptable carrier to ensure optimal delivery.

Commercial Applications:

• Treatment of Avian Bacterial Infections: Effectively combat pathogenic E. coli (APEC) and Salmonella infections in chickens and turkeys.
• Prevention of Human Health Risks: By treating bacterial infections in avian populations, the technology helps reduce the risk of transmission to humans through contaminated poultry products.
• Poultry Industry Advancement: Minimize economic losses and improve productivity in the poultry industry by curbing the spread of APEC and Salmonella outbreaks.
• Antibiotic Adjunct: The antimicrobial peptide can be used in combination with antibiotic therapies, enhancing their effectiveness and potentially reducing antibiotic usage.
• Veterinary and Livestock Management: The technology can be integrated into veterinary practices and livestock management protocols to safeguard avian populations.

Benefits/Advantages:

• High Effectiveness: The antimicrobial peptide exhibits potent activity against APEC and Salmonella strains, providing reliable and rapid treatment.
• Reduced Antibiotic Resistance: By targeting bacterial membranes, the technology offers an alternative to traditional antibiotics, minimizing the development of resistant strains.
• Specificity and Safety: The peptide's targeted action on bacterial membranes ensures safety for avian populations while sparing beneficial microorganisms.
• Sustainable Poultry Production: With a reduced reliance on conventional antibiotics, the technology supports sustainable and responsible poultry production practices.
• Human Health Protection: By preventing the spread of infections to humans through poultry products, the technology contributes to public health protection.

In conclusion, the advanced antimicrobial peptide therapy described herein offers a compelling solution to address the commercial need for combating avian bacterial infections caused by pathogenic E. coli (APEC) and Salmonella strains (ST and SE). With its high effectiveness, reduced resistance development, and safety advantages, the technology holds great promise for the poultry industry and public health alike.